24
Participants
Start Date
January 31, 2006
Primary Completion Date
March 31, 2010
Study Completion Date
March 31, 2010
capecitabine
This is a dose escalation study. 375, 500, 650, or 850 mg/m2 capecitabine RDT is given orally daily in two divided doses approximately 12 hours apart beginning at the start of radiation therapy and continuing for 9 weeks. After a two week break, patients receive twice daily oral capecitabine, either 900 mg/m2 or 1250 mg/m2, approximately 12 hours apart for 14 days followed by a 7-day rest period for a total of 3 courses.
radiation therapy
Participants receive local radiation once daily, 5 days/week for 9 weeks for a total dose of 5580 cGy.
Children's Hospital of Pittsburgh, Pittsburgh
Duke Comprehensive Cancer Center, Durham
St. Jude Children's Research Hospital, Memphis
Children's Memorial Hospital - Chicago, Chicago
Dan L. Duncan Cancer Center at Baylor College of Medicine, Houston
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Children's Hospital and Regional Medical Center - Seattle, Seattle
Children's National Medical Center, Washington D.C.
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston
Children's Hospital of Philadelphia, Philadelphia
Texas Children's Cancer Center and Hematology Service at Texas Children's Hospital, Houston
National Cancer Institute (NCI)
NIH
Pediatric Brain Tumor Consortium
NETWORK